ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA

Key Points

• ADAR1 Capital Management acquired 130,152 shares of Aura Biosciences valued at approximately $924,000, representing about 0.13% of the company. Institutional investors and hedge funds collectively own 96.75% of AURA.
• Analyst sentiment is mixed, with two Buy ratings and one Sell rating producing a consensus “Hold” rating and a $17.50 price target. HC Wainwright recently reduced its target from $24 to $18.
• AURA shares opened at $7.82, while Aura reported a quarterly loss of $0.48 per share, missing the $0.38 consensus estimate; analysts expect a full-year loss of $1.61 per share.

ADAR1 Capital Management LLC bought a new position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 130,152 shares of the company's stock, valued at approximately $924,000. ADAR1 Capital Management LLC owned approximately 0.13% of Aura Biosciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AURA. Legal & General Group Plc acquired a new position in shares of Aura Biosciences during the 2nd quarter worth about $29,000. Parallel Advisors LLC increased its stake in Aura Biosciences by 130.4% in the first quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock valued at $38,000 after purchasing an additional 3,206 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after purchasing an additional 2,104 shares in the last quarter. Water Island Capital LLC purchased a new stake in shares of Aura Biosciences during the 3rd quarter worth approximately $64,000. Finally, ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at $59,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AURA. Wall Street Zen downgraded Aura Biosciences from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. HC Wainwright decreased their price objective on Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 14th. Finally, Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $17.50.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $7.82 on Wednesday. The business's 50 day simple moving average is $7.23 and its 200-day simple moving average is $6.86. The firm has a market capitalization of $811.01 million, a price-to-earnings ratio of -4.47 and a beta of 0.40. Aura Biosciences, Inc. has a 12 month low of $4.73 and a 12 month high of $9.53.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). On average, equities analysts anticipate that Aura Biosciences, Inc. will post -1.61 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Anthony S. Gibney sold 12,824 shares of Aura Biosciences stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the completion of the sale, the insider owned 265,354 shares of the company's stock, valued at $1,703,572.68. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.90% of the company's stock.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. (NASDAQ:AURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source